Abstracts - faqs.org

Abstracts

News, opinion and commentary

Search abstracts:
Abstracts » News, opinion and commentary

A company tested and found wanting

Article Abstract:

Nortel Networks plummeting stock and $19.2 billion second quarter loss is considered to be a prime example of terrible management of stockholder assets. Nortel shares fell from $89 in July to a recent $9.86. Nortel chief John Roth and his board of directors represented the 'new economy' mania with 11 tech acquisitions for $19.7 billion (mostly in shares), paying a hundred times more for the companies than their value. Nortel also reported a $12.3 billion write-down in the 2nd quarter for the afore-mentioned acquisitions. Nortel shareholders have paid for the right to be angry.

Author: Morgenson, Gretchen
Publisher: The New York Times Company
Publication Name: The New York Times
Subject: News, opinion and commentary
ISSN: 0362-4331
Year: 2001
Canada, Communications Equipment, Telecommunications Equipment, Communications Equipment Manufacturing, Statistical Data Included, Management, Planning, Economic aspects, Acquisitions and mergers, Telecommunications equipment industry, Telecommunications systems, Bear market, Influence, Nortel Networks Corp., NT, Company business planning, Roth, John

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


The S.E.C.'s Infrequent Filer Plan

Article Abstract:

Securities and Exchange Commission rules allow international companies to only file reports annually instead of quarterly, which was problematic for investors in Taro Pharmaceutical Industries, which deals primarily in the United States but is based in Israel, and filed a late annual report that contradicted its current financial state.

Author: Morgenson, Gretchen
Publisher: The New York Times Company
Publication Name: The New York Times
Subject: News, opinion and commentary
ISSN: 0362-4331
Year: 2004
Government regulation (cont), Sales, profits & dividends, Government regulation, Pharmaceutical preparations, Legal/Government Regulation, Laws, regulations and rules, Pharmaceutical industry, International aspects, Company sales and earnings, Company earnings/profit, Investor relations, Corporation reports, Company reports, Taro Pharmaceutical Industries Ltd.

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


The Former Chief of A.I.G. Is Silent Before Regulators

Article Abstract:

Maurice R. Greenberg refused to incriminate himself by invoking his Fifth Amendment rights, when he was questioned by the New York Attorney General's office about the transfer of $2.6 billion of American International Group's stock. Insurance giant American International Group Inc. is being investigated for accounting irregularities.

Author: Morgenson, Gretchen
Publisher: The New York Times Company
Publication Name: The New York Times
Subject: News, opinion and commentary
ISSN: 0362-4331
Year: 2005
Securities issued, listed, INSURANCE CARRIERS, Capital funds & cash flow, Company legal issue, Insurance industry, Company investment, Investments, Investigations, Accounting and auditing, Behavior, American International Group Inc., Securities, Company securities, AIG, Greenberg, Hank (American chief executive officer)

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: United States, United States. Securities and Exchange Commission
Similar abstracts:
  • Abstracts: Fund company trims time for conversion of B shares. Fidelity's president has familiar name. Vanguard refuses to be shaken
  • Abstracts: Telecom firms hook $4B deal. Lucent ditches Alcatel at last second. Lucent, Alcatel agree to merger talks
  • Abstracts: Labor mark I. The face of new labor. The contender
  • Abstracts: Only fools rush in. Advance warning. Seeds of doubt
  • Abstracts: Algoma survival in workers' hands. Algoma gets creditor protection
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.